4/A: Beam Therapeutics CEO Discloses Previously Omitted Stock Option Exercise in Amended SEC Filing
SEC Form 4/A
Beam Therapeutics CEO John M. Evans files an amended SEC Form 4/A to disclose a prior stock option exercise that was inadvertently omitted from the original filing.
Summary
- John M. Evans, CEO of Beam Therapeutics Inc., filed an amended SEC Form 4/A on April 2, 2025, to correct an omission in the original Form 4 filed on February 3, 2025.
- The amendment discloses the exercise of stock options for 30,000 shares of common stock at a price of $0.67 per share on January 30, 2025.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 14, 2024.
- Following the disclosed transaction, Evans directly beneficially owned 968,659 shares of Beam Therapeutics.
- As of the date of the amended filing, Evans directly beneficially owns 938,659 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing is a correction of a previous omission, and while it doesn't indicate any fundamental issues with the company, it does highlight a minor lapse in reporting.
Negatives
- The original Form 4 filing contained an omission, requiring an amendment to correct the record.
Risks
- Omissions in SEC filings, even if unintentional, can raise concerns about transparency and internal controls.
Industry Context
This filing is a routine disclosure related to insider trading activity, which is common among publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to allow insiders to sell shares without being accused of trading on non-public information.
Comparison to Industry Standards
- Similar filings are common across the biotechnology industry, with executives and directors regularly reporting transactions in their company's stock.
- Companies like CRISPR Therapeutics and Editas Medicine also have executives who utilize 10b5-1 trading plans to manage their stock holdings.
Stakeholder Impact
- The correction of the filing ensures transparency for shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| May 8, 2018 | Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering |
| June 14, 2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| January 30, 2025 | Date of the stock option exercise transaction. |
| February 3, 2025 | Date of the original Form 4 filing that contained an omission. |
| April 2, 2025 | Date of the amended Form 4/A filing. |
Keywords
SEC Filing, Form 4/A, Beam Therapeutics, Stock Options, Beneficial Ownership, Rule 10b5-1, Insider Trading, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.